leadXpro to Work With Creoptix Wave Technology for Their Membrane Protein Drug Discovery Projects
VILLIGEN, Switzerland, November 15, 2017 (Newswire.com) - Creoptix and leadXpro AG announce the selection of the Creoptix WAVE technology by leadXpro to strengthen its capabilities for drug discovery aimed at identifying and optimizing drug candidates directed against challenging membrane protein drug targets.
Creoptix provides leadXpro with the Creoptix WAVEdelta system, its latest technology for real-time label-free molecular interaction analysis. The WAVEdelta combines the highest sensitivity and the broadest sample compatibility, which is especially important when working with membrane proteins. leadXpro will combine the WAVE technology with its expertise in assay development, high throughput screening, membrane protein generation, structure determination and application of further biophysical methods. Accurate characterization of the speed at which drug molecules bind to and dissociate from their therapeutic target helps to fine-tune the design of new drug molecules. leadXpro researchers will investigate the interaction of small molecules and biotherapeutics with ion channels, transporters and G-protein receptors to facilitate the discovery and optimization of novel drug lead molecules.
Nicolas Bocquet (Senior Scientist, leadXpro) said: “The combination of unique technology, robustness, flexibility in designing a broad range of assays and high sensitivity, enabling even fragment-sized molecules to be screened and characterized, made the Creoptix WAVEdelta the instrument investment of our choice. Thorough testing in our laboratory has convinced us that Creoptix’s WAVE technology aids us best in discovering better drug molecules."
Matyas Vegh (CEO, Creoptix) said: “leadXpro scientists are experts in the field of membrane protein drug targets and they rigorously evaluated our system against several competitors. It makes us very proud that they selected the Creoptix WAVEdelta as their system to analyse kinetics and affinity in real-time.”
Creoptix is a privately held company founded in 2009 and headquartered in Wädenswil, near Zurich, Switzerland, and offices near Boston, U.S. Creoptix focuses on the development of next-generation instruments for the high-sensitivity kinetics and affinity analysis of label-free molecular interactions based on innovative, proprietary technology. Based on proprietary technology, the Creoptix WAVE systems provide exceptionally high sensitivity and resolution at even very low signal levels, fastest kinetics and a compatibility with crude samples like undiluted serum or plasma, cell supernatant, crude membrane extracts or large particles like viruses, VLPs or liposomes.
For more information, please visit www.creoptix.com.
About leadXpro AG
leadXpro is a lead discovery company focusing on membrane protein drug targets. We are committed to the application of biophysical and structure-based methods for the discovery and optimization of next-generation lead compounds for challenging GPCRs, ion-channels and transporters. We capitalize on the knowledge regarding membrane protein generation, structural biology and facilities of the Paul Scherrer Institute (PSI) with premium access to the synchrotron Swiss Light Source (SLS) and the Free Electron Laser (SwissFEL). Core expertise beyond X-ray includes single particle cryo-electron microscopy (cryo-EM). For more information, please visit www.leadxpro.com.
leadXpro is a registered trademark in the EU, Switzerland, US and Canada.